The key growth drivers for the pharmaceutical industry in India include the country's growing economy, expanding health insurance coverage and healthcare expenditure, and use of expired foreign brands and branded generics, especially among the middle classes. This has prompted multinational companies to expand their presence in India.
Scope of this research
- Analysis of population demographics, economic wealth, disease burden, level of industrialization, and political structure in India.
- Insight into the healthcare system, drug regulation, drug pricing, drug reimbursement, and intellectual property position in India.
- Assesses the generics and biosimilars landscape in terms of regulatory issues, level of penetration, and key players in India.
- Overview of R&D and manufacturing infrastructure for the leading pharmaceutical companies in India.
Research and analysis highlights
India's expanding and ageing population, together with its growing economic wealth are driving drug expenditure, a trend which is putting pressure on the government to provide better healthcare services a move which will further stimulate pharma market growth.
However, until government efforts to improve healthcare coverage for the poor are expanded, most drug expenditure will be derived from the upper and middle classes who are increasingly suffering from Western type of diseases and are turning towards foreign branded drugs.
Domestic manufacturers dominate the Indian pharmaceutical market, with generics accounting for over 99% of the total market volume and 20% of market value. Despite market saturation, uptake is and will continue to be driven primarily by the growing number of patients gaining access to affordable medicines, with branding critical for success.
Key reasons to purchase this research
- Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in India.
- Assess drivers and resistors of generic and biosimilars uptake in the Indian pharmaceutical market.
- Review the evolving pharmaceutical infrastructure for the leading companies in India, and how they have been impacted by industry challenges.